MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference (EST TIME ZONE)

20th - 23rd October 2020
Sponsors
Platinum

QIAGEN

QIAGEN

Every day, QIAGEN serves 500,000 customers globally, all seeking insights from DNA and RNA. Delivering Sample to Insight solutions for molecular testing, we help scientists and clinicians achieve breakthroughs in life sciences research, molecular diagnostics and drug development. This is how we make improvements in life possible. In healthcare and academic institutions, and drug-discovery and forensic laboratories, QIAGEN solutions advance disease detection and treatments, enable precision medicine, and aid crime detection and human identification.

Gold

Burning Rock

Burning Rock

Burning Rock Dx specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. With the unique capability and experience in global trials, we seek partnerships to advance the field of companion diagnostics in order to achieve better patient outcomes.


Owlstone Medical

Owlstone Medical

Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the potential of breath biomarkers for early detection and precision medicine through Breath Biopsy®. Breath Biopsy provides reliable solutions for the collection and analysis of volatile organic compounds (VOCs) produced through metabolic processes or as a result of interaction with external factors such as diet or medication. Changes to exhaled VOCs can be associated with a range of disease conditions and environmental exposures.

 


Agilent

Agilent

Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. With over 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions.

Agilent brings the power of precision medicine to customers, partners, and patients.  Agilent is a partner of choice to pharmaceutical and biotech companies producing innovative diagnostics and therapeutics for the benefit of patients around the world.

Silver

Larvol

Larvol

Committed to healthcare since 2004, LARVOL has been delivering custom intelligence solutions that provide healthcare and life sciences experts accurate, rapid, expertly-curated information to enable strategic decision-making. Specifically in the oncology space, we collate and simplify data from over 25,000 sources and offer novel tools to extract meaningful insights. Our newest product CLIN delivers the complete universe of immuno-oncology clinical trial data in one, easy-to-navigate platform. That's ten years of trial data, manually reviewed and coded to extract every table, graph, and figure. New data is added as it's released from publications, conferences, and guidelines.


Abcam

Abcam

As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.

Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company’s proprietary discovery platforms and world-leading, antibody expertise.

Sponsors & Exhibitors

Proteome Sciences

Proteome Sciences

We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry.  By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.

With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.

Speaking Partner

NeoGenomics

NeoGenomics

NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced oncology patient care leveraging the most extensive diagnostic solid tumor and hematological test menus, sub-specialized pathology, and expertise in biomarker development. We partner closely with our pharma and research clients to meet program objectives and delivery from biomarker discovery through CDx validation and commercialization.


Eutropics

Eutropics

Eutropics, a clinical diagnostics company, is developing novel, functional assays that enable personalized medicine approaches to treating cancer.

Eutropics’ PraediCare DxTM platform delivers medically useful insight that accelerates drug development and guides treatment.

Based on the principles of apoptosis biology, the Praedicare DxTM  platform provides predictive functional biomarkers for liquid ad solid cancers.

The Mcl-1 Dependency Assay is a Laboratory Developed Test (LDT) for Alvocidib, and becoming a companion diagnostic for other MCL1 targeting therapies.


RareCyte

RareCyte

RareCyte provides Precision Biology™ solutions for liquid biopsy and highly multiplexed tissue imaging. The comprehensive portfolio enables CTC characterization and single cell retrieval for molecular analysis, CTC-based CDx development, as well as deep phenotyping and spatial analysis via 21-plex fluorescence imaging, and micro-region retrieval for immuno-oncology applications.


Cureline

Cureline

Cureline, Inc. is a global contract research organization (CRO) and a commercial biobank supporting preclinical research in oncology, hematology, immune-oncology and various other therapeutic areas (Cardio-vascular, metabolic, neuro-degenerative, infectious and inherited conditions) to the pharmaceutical, biotechnology, and medical device industries worldwide since 2003.

 

Meeting Partner

International Drug Development Institute

International Drug Development Institute

IDDI provides biostatistical and eClinical services to pharmaceutical and biotech companies since 1991.

  • Advanced knowledge in statistical validation of diagnostic, predictive, prognostic & surrogate biomarkers: 55+ trials, 60+ publications.
  • Expert skills in :
  • Analytical validation in line with development stage (IDE, IVD, following CLSI)
  • Clinical validation:
    • Statistical strategies for 510(k) and PMA studies
    • Bridging studies for companion diagnostics
    • Advanced statistical methodology to validate biomarkers in absence of  gold standard
  • Oncology and immune-oncology

Biodesix

Biodesix

Biodesix® is an experienced blood-based diagnostic solutions company with a clinical focus in lung cancer. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by profiling both the tumor and immune system. Biodesix creates end-to-end solutions with our biopharma partners from initial biomarker discovery  to companion diagnostic partnering, including commercialization and reimbursement.